Pain treatment with NSAIDs, primary focus on ibuprofen

Area of Science:

• Pharmacology
• Drug Safety
• Gastroenterology

Background:

• Ibuprofen, a widely used non-steroidal anti-inflammatory drug (NSAID), is available over-the-counter in some countries.
• Despite its safety profile, all NSAIDs carry risks, including gastrointestinal toxicity, fluid retention, and kidney issues.
• Newer NSAIDs, such as COX-2 inhibitors and single enantiomer drugs like S(+) ibuprofen (dexibuprofen), have been developed to improve safety.

Purpose of the Study:

• To review the safety profiles of ibuprofen and newer NSAID alternatives.
• To compare the adverse effects of racemic ibuprofen with COX-2 inhibitors.
• To highlight the need for comparative studies between COX-2 inhibitors and dexibuprofen.

Main Methods:

• Literature review of studies comparing NSAIDs.
• Analysis of clinical adverse event rates.
• Examination of upper gastrointestinal ulcer complication data.

Main Results:

• Previous studies found no significant difference in overall adverse experiences between rofecoxib and racemic ibuprofen.
• Celecoxib showed a statistical advantage over ibuprofen for upper GI ulcer complications in patients not taking aspirin.
• S(+) ibuprofen (dexibuprofen) offers equipotency with half the dose of racemic ibuprofen, allowing for lower prescribed amounts.

Conclusions:

• While ibuprofen is generally safe, newer NSAIDs like dexibuprofen and COX-2 inhibitors offer potential safety benefits.
• Comparative data suggests some COX-2 inhibitors may have an edge over ibuprofen for specific gastrointestinal risks.
• Further research directly comparing COX-2 inhibitors with dexibuprofen is essential for guiding clinical practice.